Today: 30 April 2026
P&G stock price heads into Monday on JPMorgan upgrade as Fed week looms
25 January 2026
1 min read

P&G stock price heads into Monday on JPMorgan upgrade as Fed week looms

NEW YORK, Jan 25, 2026, 11:19 AM EST — Market closed.

  • JPMorgan raised its price target for Procter & Gamble, joining Wells Fargo and UBS in boosting their own estimates.
  • PG shares closed Friday at $150.15, with U.S. markets offline for the weekend.
  • This week’s Fed decision and crucial consumer data have investors focused on what’s next.

JPMorgan lifted Procter & Gamble to Overweight from Neutral, boosting its price target to $165 from $157, TheFly reports. P&G shares closed Friday at $150.15, up 0.15%, and will resume trading when markets open Monday.

The timing is crucial. P&G remains a core holding for numerous funds, often drawing capital from investors seeking reliable earnings—even if growth tapers off.

The quarter revealed a clear tension within the business — prices stayed firm, but demand weakened. P&G reported “organic sales” — which exclude currency effects and acquisitions or divestitures — were flat. Core earnings per share, adjusted for one-time items, came in at $1.88. CEO Shailesh Jejurikar confirmed the company is still on track to meet its fiscal-year guidance. Procter Gamble

JPMorgan analyst Andrea Teixeira expects P&G to pick up organic sales growth and boost margins, saying the “worst seems behind” following increased investment. She added, “We give PG the benefit of the doubt,” though she warned of execution risks tied to regaining market share. Investors.com

Wells Fargo’s Chris Carey bumped his price target on Procter & Gamble to $165 from $158, maintaining an Overweight rating. Carey noted, “If U.S. data improves, Procter & Gamble works,” highlighting the “if” as the key uncertainty. TipRanks

UBS bumped its price target to $170 from $161 and stuck with a Buy rating, noting that P&G beat estimates in the second quarter while maintaining its fiscal 2026 guidance.

In its latest quarterly filing, P&G revealed it repurchased around $2.3 billion in shares and paid a dividend of $1.0568 per share. The company also flagged tariff expenses and product mix as headwinds impacting gross margin in certain segments.

Traders are now eyeing whether the stock can stay above $150 without a new catalyst. P&G’s lineup — including Tide, Pampers and Gillette — is closely tied to consumer behavior, and its pricing and volume trends could ripple through peers like Kimberly-Clark, Colgate-Palmolive and Unilever.

The boost from upgrades could vanish quickly if U.S. consumer spending remains weak, retailers resist raising prices, or costs surge again. Rising rates wouldn’t offer relief either; dividend-heavy defensive stocks tend to stumble as bond yields climb.

The key event this week is the Federal Reserve’s policy announcement on Wednesday, Jan. 28, set for 2 p.m. ET, followed by Chair Jerome Powell’s press briefing at 2:30 p.m. ET. On Tuesday, the U.S. consumer confidence report drops at 10 a.m. ET.

Stock Market Today

  • Xanadu Quantum Technologies Shares Surge Amid Growing Revenue but Deep Losses
    April 30, 2026, 3:29 PM EDT. Xanadu Quantum Technologies (TSX:XNDU) recently saw its shares jump 134% for the year, fueled by excitement around its photonic quantum computing platform. The company reported CA$4.617 million in revenue, mostly from the US, marking a robust 62% annual growth. However, it posted a hefty CA$70.7 million net loss, reflecting ongoing heavy investment in development. Its market capitalization stands near CA$11.65 billion despite the losses. Xanadu trades with an unusual price-to-book (P/B) ratio of around -43.5, far from typical tech sector multiples, due to negative equity and ongoing deficits. This valuation gap highlights the challenge in assessing quantum computing firms where traditional metrics offer limited insight. Investors remain cautious over whether the recent price surge fairly values future growth potential.

Latest article

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

30 April 2026
Stellantis reported a first-quarter net profit of €377 million, reversing a €387 million loss a year earlier, aided by a €400 million expected U.S. tariff refund. Industrial free cash flow remained negative at €1.92 billion. Shares fell 6.4% to €6.22 after the results. CEO Antonio Filosa faces pressure ahead of a May 21 investor day to present a stronger turnaround plan.
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings
Previous Story

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

American Express stock slides into earnings week as Fed decision looms — what to watch next
Next Story

American Express stock slides into earnings week as Fed decision looms — what to watch next

Go toTop